IDL Biotech has chosen QAdvis for regulatory guidance and support

QAdvis has signed an agreement with IDL Biotech. We are proud to be a part of this exciting collaboration in which we will plan and conduct clinical studies for the IVD test UBC® Rapid.

Based on the results, QAdvis will provide further regulatory guidance and support to IDL with the FDA application. As part of the collaboration, QAdvis U.S. partner New World Regulatory Solutions, Inc. is also engaged in the project.

UBC® Rapid is intended for the detection of bladder cancer in particular in high-risk patients and to monitor the development of the disease after an established diagnosis.

Read more at;

IDL Biotech Webpage

News at Cision Newsroom (swedish)

QAdvis News #3 – 2020